Expanesthetics

Expanesthetics is a private, preclinical-stage biotech based in San Diego, focused on revolutionizing inhaled anesthesia through a proprietary discovery engine. The company's platform, rooted in research from UC Davis, uses molar water solubility to predict receptor activity and design anesthetics that target specific neural pathways to reduce side effects. It has generated a pipeline of novel drug candidates, including the first non-ether anesthetic in over 60 years to reach its stage, showing promising preclinical results such as maintaining normal blood pressure. Expanesthetics aims to address a large, underserved market dominated by decades-old generic drugs.

A proprietary discovery platform that uses molar water solubility as a predictive tool to design novel inhaled anesthetics. It aims to create compounds that selectively modulate specific neural receptors (e.g., GABA-A) while avoiding others (e.g., NMDA) to reduce side effects and enable new chemical classes.

The competitive landscape is dominated by generic manufacturers of established agents (sevoflurane, desflurane). There are few, if any, companies actively developing new mechanistic classes of inhaled anesthetics, giving Expanesthetics a potential first-mover advantage if its technology is validated.